|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bone marrow derived stem cells for the treatment of end-stage liver disease显示文摘End-stage disease due to liver cirrhosis is an important cause of death worldwide. Cirrhosis results from progressive, extensive fibrosis and impaired hepatocyte regeneration. The only curative treatment is liver transplantation, but due to the several limitations of this procedure, the interest in alternative therapeutic strategies is increasing. In particular, the potential of bone marrow stem cell(BMSC) therapy in cirrhosis has been explored in different trials. In this article, we evaluate the results of 18 prospective clinical trials, and we provide a descriptive overview of recent advances in the research on hepatic regenerative medicine. The main message from the currently available data in the literature is that BMSC therapy is extremely promising in the context of liver cirrhosis. However, its application should be further explored in randomized, controlled trials with large cohorts and long follow-ups. | Cristina Margini Ranka Vukotic Lucia Brodosi Mauro Bernardi Pietro Andreone | 2014 | World Journal of Gastroenterology2014，20，27： | 18 |
| 2 | Stem cells for end stage liver disease: How far have we got?显示文摘End stage liver disease (ESLD) is a health problem worldwide. Liver transplantation is currently the only effective therapy, but its many drawbacks include a shortage of donors, operative damage, risk of rejection and in some cases recidivism of the pre-transplant disease. These factors account for the recent growing interest in regenerative medicine. Experiments have sought to identify an optimal source of stem cells, sufficient to generate large amounts of hepatocytes to be used in bioartificial livers or injected in vivo to repair the diseased organ. This update aims to give non-stem cell specialists an overview of the results obtained to date in this fascinating field of biomedical research. | Stefania Lorenzini Stefano Gitto Elena Grandini Pietro Andreone Mauro Bernardi | 2008 | World Journal of Gastroenterology2008，14，29： | 8 |
| 3 | Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature显示文摘The scarcity of available organs and the gap between supply and demand continue to be the main limitations of liver transplantation. To relieve the organ shortage, current transplant strategies have implemented extended criteria, which include the use of liver from patients with signs of past or present hepatitis B virus(HBV) infection. While the use of liver grafts from donors with evidence of past HBV infection is quite limited, some data have been collected regarding the feasibility of transplanting a liver graft from a hepatitis B surface antigen(HBs Ag) positive donor. The aim of the present work was to review the literature regarding liver transplants from HBs Ag-positive donors. A total of 17 studies were identified by a search in Medline. To date, HBs Ag positive grafts have preferentially been allocated to HBs Ag positive recipients. The large majority of these patients continue to be HBs Ag positive despite the use of immunoglobulin, and infection prevention can only be guaranteed by using antiviral prophylaxis. Although serological persistence is evident, no significant HBV-related disease has been observed, except in patients coinfected with delta virus. Consistently less data are available for HBs Ag negative recipients, although they are mostly promising. HBs Agpositive grafts could be an additional organ source for liver transplantation, provided that the risk of reinfection/reactivation is properly prevented. | Elisabetta Loggi Fabio Conti Alessandro Cucchetti Giorgio Ercolani Antonio Daniele Pinna Pietro Andreone | 2016 | World Journal of Gastroenterology2016，22，35： | 5 |
| 4 | De novo autoimmune hepatitis in liver transplant: State-of-the-art review显示文摘In the two past decades, a number of communications, case-control studies, and retrospective reports have appeared in the literature with concerns about the development of a complex set of clinical, laboratory and histological characteristics of a liver graft dysfunction that is compatible with autoimmune hepatitis. The de novo prefix was added to distinguish this entity from a pre-transplant primary autoimmune hepatitis, but the globally accepted criteria for the diagnosis of autoimmune hepatitis have been adopted in the diagnostic algorithm. Indeed, de novo autoimmune hepatitis is characterized by the typical liver necroinflammation that is rich in plasma cells, the presence of interface hepatitis and the consequent laboratory findings of elevations in liver enzymes, increases in serum gamma globulin and the appearance of nonorgan specific auto-antibodies. Still, the overall features of de novo autoimmune hepatitis appear not to be attributable to a univocal patho-physiological pathway because they can develop in the patients who have undergone liver transplantation due to different etiologies. Specifically, in subjects with hepatitis C virus recurrence, an interferon-containing antiviral treatment has been indicated as a potential inception of immune system derangement. Herein, we attempt to review the currently available knowledge about de novo liver autoimmunity and its clinical management. | Ranka Vukotic Giovanni Vitale Antonia D'Errico-Grigioni Luigi Muratori Pietro Andreone | 2016 | World Journal of Gastroenterology2016，22，10： | 4 |
| 5 | Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach显示文摘 | Calogero Cammà Marco Giunta Pietro Andreone Antonio Crax?? | 2001 | Journal of Hepatology2001，，4： | 2 |
| 6 | Liver transplantation from hepatitis B surface antigen positive donors: A safe way to expand the donor pool显示文摘 | Elisabetta Loggi Lorenzo Micco Giorgio Ercolani Alessandro Cucchetti Florian K. Bihl Gian Luca Grazi Stefano Gitto Andrea Bontadini Mauro Bernardi Paolo Grossi Alessandro Nanni Costa Antonio Daniele Pinna Christian Brander Pietro Andreone | 2011 | Journal of Hepatology2011，，3： | 2 |
| 7 | Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis:a systematic review and meta-analysis显示文摘AIM To assess vitamin E efficacy,defined as its ability to induce hepatitis B e antigen(HBeAg) seroconversion,in children with HBeAg-positive persistent hepatitis.METHODS In July 2016,we extracted articles published in MEDLINE and the Cochrane Library using the following search terms:'chronic hepatitis B','children','childhood','therapy','treatment','vitamin E','tocopherols','tocotrienols'.Only randomized controlled trials(RCTs) published in English language were collected.RESULTS Three RCTs met inclusion criteria and were considered in the present meta-analysis.Overall,23/122 children in the treatment group underwent HBeAg seroconversion vs 3/74 in the control group(OR=3.96,95%CI:1.18-13.25,P=0.025).CONCLUSION Although our meta-analysis has several limits,including the very small number of available studies and enrolled children with HBeAg positivity-related hepatitis,it suggests that vitamin E use may enhance the probability to induce HBeAg seroconversion in these patients.Further well designed and adequately sized trials are required to confirm or deny these very preliminary results. | Sirio Fiorino Maria Letizia Bacchi-Reggiani Paolo Leandri Elisabetta Loggi Pietro Andreone | 2017 | World Journal of Hepatology2017，9，6： | 2 |
| 8 | Hepatitis C virus recurrence after liver transplantation:A 10-year evaluation显示文摘AIM: To evaluate the predictors of 10-year survival of patients with hepatitis C recurrence. METHODS: Data from 358 patients transplanted between 1989 and 2010 in two Italian transplant centers and with evidence of hepatitis C recurrence were analyzed. A χ2, Fisher's exact test and Kruskal Wallis' test were used for categorical and continuous variables, respectively. Survival analysis was performed at 10 years after transplant using the Kaplan-Meier method, and a log-rank test was used to compare groups. A P level less than 0.05 was considered significant for all tests. Multivariate analysis of the predictive role of different variables on 10-year survival was performed by a stepwise Cox logistic regression.RESULTS: The ten-year survival of the entire population was 61.2%. Five groups of patients were identified according to the virological response or lack of a response to antiviral treatment and, among those who were not treated, according to the clinical status(mild hepatitis C recurrence, 'too sick to be treated' and patients with comorbidities contraindicating the treatment). While the 10-year survival of treated and untreated patients was not different(59.1% vs 64.7%, P = 0.192), patients with a sustained virological response had a higher 10-year survival rate than both the 'non-responders'(84.7% vs 39.8%, P < 0.0001) and too sick to be treated(84.7% vs 0%, P < 0.0001). Sustained virological responders had a survival rate comparable to patients untreated with mild recurrence(84.7% vs 89.3%). A sustained virological response and young donor age were independent predictors of 10-year survival. CONCLUSION: Sustained virological response significantly increased long-term survival. Awaiting the interferon-free regimen global availability, antiviral treatment might be questionable in selected subjects with mild hepatitis C recurrence. | Stefano Gitto Luca Saverio Belli Ranka Vukotic Stefania Lorenzini Aldo Airoldi Arrigo Francesco Giuseppe Cicero Marcello Vangeli Lucia Brodosi Arianna Martello Panno Roberto Di Donato Matteo Cescon Gian Luca Grazi Luciano De Carlis Antonio Daniele Pinna Mauro Bernardi Pietro Andreone | 2015 | World Journal of Gastroenterology2015，21，13： | 2 |
| 9 | ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV Genotype 1b Infection显示文摘 | Pietro Andreone Massimo G. Colombo Jeffrey V. Enejosa Iftihar Koksal Peter Ferenci Andreas Maieron Beat Müllhaupt Yves Horsmans Ola Weiland Henk W. Reesink Lino Rodrigues Yiran B. Hu Thomas Podsadecki Barry Bernstein | 2014 | Gastroenterology2014，，： | 2 |
| 10 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 2 |
| 11 | Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation显示文摘 | Scott K. Fung Pietro Andreone Steve H. Han K. Rajender Reddy Arie Regev Emmet B. Keeffe Munira Hussain Carmela Cursaro Pamela Richtmyer Jorge A. Marrero Anna S.F. Lok | 2005 | Journal of Hepatology2005，，6： | 1 |
| 12 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 1 |
| 13 | Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach显示文摘 | Calogero Cammà Marco Giunta Pietro Andreone Antonio Crax?? | 2001 | Journal of Hepatology2001，，4： | 1 |
| 14 | Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV显示文摘 | Paola Fisicaro Caterina Valdatta Marco Massari Elisabetta Loggi Lara Ravanetti Simona Urbani Tiziana Giuberti Albertina Cavalli Carmen Vandelli Pietro Andreone Gabriele Missale Carlo Ferrari | 2012 | Gastroenterology2012，，6： | 1 |
| 15 | Sustained virologic response rates with telaprevir by response after 4<ce:hsp sp='0.25'/>weeks of lead-in therapy in patients with prior treatment failure显示文摘 | Graham R. Foster Stefan Zeuzem Pietro Andreone Stanislas Pol Eric J. Lawitz Moises Diago Stuart Roberts Paul J. Pockros Zobair Younossi Isabelle Lonjon-Domanec Sandra De Meyer Don Luo Shelley George Maria Beumont Gaston Picchio | 2012 | Journal of Hepatology2012，，： | 1 |
| 16 | Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation显示文摘 | Scott K. Fung Pietro Andreone Steve H. Han K. Rajender Reddy Arie Regev Emmet B. Keeffe Munira Hussain Carmela Cursaro Pamela Richtmyer Jorge A. Marrero Anna S.F. Lok | 2005 | Journal of Hepatology2005，，6： | 1 |
| 17 | Ketoprofen,peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C:A phaseⅡ study显示文摘AIM:To evaluate the safety of adding ketoprofen to pegylated-interferon(PEG-IFN)with or without ribavirin and the effect on viral kinetics,STAT1 activity and expression of 2'-5'-oligoadenylate synthetase (2'-5'OAS)in genotype 1 chronic hepatitis C in a phaseⅡstudy. METHODS:Forty-five patients were studied:fifteen were randomized to PEG-IFN plus ribavirin(PR),16 to PEGIFN plus ketoprofen and 14 to PR and ketoprofen.Themolecular study of IFN-dependent signal transduction was conducted in 9 patients from each group. RESULTS:The combination of ketoprofen and PEG- IFN with or without ribavirin was safe and well tolerated.An early activation of STAT1 was observed in ke-toprofen-treated patients,but this activation was less sustained over time.Conversely,ketoprofen plus PEG- IFN and ribavirin induced an early and sustained increase of 2'-5'OAS transcription starting 24 h after the first dose until the 36th wk.These data are consistent with the clinical results,showing a better sustained virological response and a lower relapse rate in patients receiving ketoprofen plus PEG-IFN and ribavirin. CONCLUSION:The addition of ketoprofen to the standard therapy of chronic hepatitis C should be explored in larger randomized clinical studies. | Annagiulia Gramenzi Carmela Cursaro Marzia Margotti Clara Balsano Alessandra Spaziani Simona Anticoli Elisabetta Loggi Maddalena Salerno Silvia Galli Giuliano Furlini Mauro Bernardi Pietro Andreone | 2009 | World Journal of Gastroenterology2009，15，47： | 1 |
| 18 | Long-term antiviral treatment for recurrent hepatitis C after liver transplantation显示文摘 | Valentina Rosa Bertuzzo Matteo Cescon Maria Cristina Morelli Paolo Di Gioia Mariarosa Tamè Stefania Lorenzini Pietro Andreone Giorgio Ercolani Massimo Del Gaudio Matteo Ravaioli Alessandro Cucchetti Alessandro Dazzi Antonietta D’Errico-Grigioni Antonio Da | 2012 | Digestive and Liver Disease2012，，10： | 1 |
| 19 | Long Term Follow-up and Outcome of Liver Transplantation for Alcoholic Liver Disease: A Single Center Case-control Study显示文摘 | Maurizio Biselli Annagiulia Gramenzi Massimo Del Gaudio Matteo Ravaioli Giovanni Vitale Stefano Gitto Gian Luca Grazi Antonio Daniele Pinna Pietro Andreone Mauro Bernardi | 2010 | Journal of Clinical Gastroenterology2010，，1： | 1 |
| 20 | Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C显示文摘 | Elisabetta Loggi Carmela Cursaro Alessandra Scuteri Elena Grandini Arianna Martello Panno Silvia Galli Giuliano Furlini Mauro Bernardi Claudio Galli Pietro Andreone | 2012 | Journal of Clinical Virology2012，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员